Cited by 72Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesTryptophan and brain disorders

Treatment of neurocognitive symptoms in unipolar depression: A systematic review and future perspectives

Open access
Salagre, E., Solé, B., Tomioka, Y., Fernandes, B.S., Hidalgo-Mazzei, D., Garriga, M., Jimenez, E., Sanchez-Moreno, J. +2 more·2017·Journal of Affective Disorders

Abstract

Background Cognitive symptoms in Major Depressive Disorder (MDD) are persistent and commonly entail neurocognitive impairment and a decline in quality of life. This systematic review gathers the current scientific evidence on therapeutic strategies for neuropsychological impairment in MDD. Method A systematic search on PubMed, PsycINFO and Clinicaltrials.gov was carried out on December 2016 according to PRISMA using Boolean terms to identify interventions for the treatment of cognitive dysfunction in MDD. Only English-written articles providing original data and focusing in adults with MDD were included with no time restrictions. Results A total of 95 studies reporting data on 40 pharmacological and non-pharmacological interventions were included. Interventions were grouped into the following categories: 1) Pharmacological Therapies (antidepressants, stimulants, compounds acting on NMDA receptors, compounds acting on the cholinergic system, compounds showing anti-inflammatory or antioxidant properties, other mechanisms of action), 2) Physical Therapies and 3) Psychological Therapies, 4) Exercise. There are some promising compounds showing a positive impact on cognitive symptoms including vortioxetine, lisdexamfetamine or erythropoietin. Limitations The studies included showed significant methodological differences in heterogeneous samples. The lack of a standardized neuropsychological battery makes comparisons between studies difficult. Conclusion Current evidence is not sufficient to widely recommend the use of procognitive treatments in MDD although promising results are coming to light.

Integrity signals

Registry

Crossref · 10.1016/j.jad.2017.06.034

Cites

177 of 177 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

2 of the 179 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Salagre, E., Solé, B., Tomioka, Y., Fernandes, B. S., Hidalgo-Mazzei, D., Garriga, M., Jimenez, E., Sanchez-Moreno, J., Vieta, E., & Grande, I.
Affiliations
  • Centro de Investigación Biomédica en Red de Salud Mental (ES)
  • Universidade Federal do Rio Grande do Sul (BR)
Corresponding author
Vieta, E.
Venue
Journal of Affective Disorders
Publisher
Elsevier BV
Published
2017-10
Volume
221
Pages
205-221
ISSN
0165-0327 (ISSN-L)
OpenAlex
W2676002985
Cited by
71
References
179
Citations by year
2026: 1 · 2025: 4 · 2024: 9 · 2023: 10 · 2022: 9 · 2021: 6 · 2020: 16 · 2019: 7 · 2018: 8 · 2017: 1
FWCI
1.11
Type
journal article
Language
en
Open access
Locations
  • Journal of Affective Disorders (publishedVersion)
  • PubMed (publishedVersion)
  • Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, cc-by-nc-nd)
  • Figshare (submittedVersion, cc-by)
Funders
  • Instituto de Salud Carlos III (JR15/00012, PI16/00187, CM15/00127)
  • Ministry of Economy and Competitiveness (PI15/00283, PI12/00912, PI16/00187)
  • CIBERSAM
  • Comissionat per a Universitats i Recerca del DIUE de la Generalitat de Catalunya (2014 SGR 398)
  • Deakin University
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
major depressive disorder, neurocognitive impairment, cognitive impairment, pharmacotherapy, antidepressants, vortioxetine, lisdexamfetamine, erythropoietin, NMDA receptor antagonists, cholinergic drugs, anti-inflammatory agents, antioxidants, physical activity, psychotherapy, physiotherapy
MeSH terms
Major Depressive Disorder, Humans, Randomized Controlled Trials as Topic, Treatment Outcome, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review